Guideline for Assigning Titles to USP Dietary Supplement Monographs

Total Page:16

File Type:pdf, Size:1020Kb

Guideline for Assigning Titles to USP Dietary Supplement Monographs Guideline for Assigning Titles to USP Dietary Supplement Monographs Approved by the Nomenclature & Labeling Expert Committee on August 19, 2019 INTRODUCTION The purpose of this Guideline is to provide a systematic approach to the development of monograph titles for dietary ingredients and dietary supplement (DS) dosage forms admitted to the United States Pharmacopeia–National Formulary (USP–NF) and Dietary Supplements Compendium (DSC) published by the United States Pharmacopeial Convention (USP). There are many considerations when naming monographs for dietary ingredients and DSs. These considerations include, but are not limited to, available scientific conventions, existing products in commerce and the practices of the DS industry, USP’s historical and scientific practices, international aspects of products, their common names originating from traditional medicine, environmental and agricultural practices, regulatory status, and the labeling requirements of applicable federal regulations. This Guideline complements USP General Chapter <1121> Nomenclature and the Nomenclature Guidelines cited therein (1). This DS Guideline describes how either common names or scientific names of articles are selected for use in the monograph title. For complex articles of botanical or animal origin, the DS Guideline will explain which details should be in the monograph title versus in the Definition section with regard to species and subspecies or variety names and common synonyms, the part of the organism and its processed form, type of extract, and composition of partially purified natural complexes. The DS Guideline will also discuss assignment of titles for single chemical entity monographs and for monographs describing the article in a particular finished oral dosage form. The examples provided herein are drawn from monographs in the USP–NF and proposed Guideline monograph titles that illustrate the results of applying this guidance. However, it should be noted that this Guideline applies to USP DS monograph titles and not to NF or other non-DS monograph titles. Each monograph shall have a title that is consistent with its Definition section and that avoids ambiguity as much as possible yet is concise. A DS monograph title must accurately identify the article whose quality specifications it describes. If the title is not reflective of how the article is best known in commerce, that can be clarified in the Definition. The DS monograph title should help guide manufacturers in meeting the identity aspects of labeling for dietary ingredients and finished DS products. G01.17-01 Page 1 of 44 EFFECTIVE DATE 03\17\ 2020 Guideline for Assigning Titles to USP Dietary Supplement Monographs Many DS monograph titles were adopted before the establishment of the current title formats and nomenclature policies. Many of these existing monograph titles are aligned with current nomenclature practices, but those existing monograph titles that are not aligned with current nomenclature practices should not be interpreted as precedents for future monograph titles. Furthermore, it is preferable that existing monograph titles that do not follow the DS Guideline should be revised only on an as-needed, case-by-case basis. In this Guideline, USP–NF monograph titles are distinguished from other text by being in bold font. Hypothetical DS monograph titles illustrating the application of these guidelines are in bold and enclosed in quotation marks to distinguish them from titles of existing monographs or approved titles of monographs currently under development. Titles of monographs currently in the Food Chemicals Codex (FCC) or Herbal Medicines Compendium (HMC) are not in bold to reduce the chance of confusion between the different compendia. The DS Guideline was developed by the USP Dietary Supplements and Herbal Medicines Nomenclature Joint Subcommittee (DSHM Nomenclature JS) with input from the USP Nomenclature and Labeling Expert Committee (NL EC), the Botanical Dietary Supplements and Herbal Medicines Expert Committee (BDSHM EC), and the Non- Botanical Dietary Supplements Expert Committee (NBDS EC). All titles of dietary ingredient monographs and DS monographs have been approved by the Nomenclature and Labeling EC with the concurrence of the appropriate EC, based on USP staff research and the best scientific judgment of the ECs. GENERAL CONSIDERATIONS Historical Practice The first Pharmacopoeia of the United States of America, published in 1820 (2), included monographs of articles that today may be marketed as DSs. These articles include some minerals (medicinal and nutritional) and many botanicals. During its first 100 years, from 1820 through 1920, around 875 botanical monographs were published in the USP. Vitamin monographs were incorporated later – the USP established a Vitamin Advisory Board in 1932, and the very first USP reference standards distributed were Vitamins A & D in Cod Liver Oil. In 1993, in response to the Nutrition Labeling and Education Act (NLEA) of 1990, a separate compendium section titled Nutritional Supplements was created to contain monographs for vitamins and minerals. DS monographs were started in 1995 in response to the Dietary Supplement Health and Education Act of 1994 (DSHEA) and included some monographs for botanicals that G01.17-01 Page 2 of 44 EFFECTIVE DATE 03\17\ 2020 Guideline for Assigning Titles to USP Dietary Supplement Monographs were originally placed in the NF. The Nutritional Supplements section was active through the publication of USP 26–NF 21 in 2003. In 2004, a new section, Dietary Supplements, was introduced into USP 27–NF 22 to replace the Nutritional Supplements section. The Dietary Supplements section includes monographs for ingredients and dosage forms of DSs as defined by DSHEA. Some monographs for botanical articles originally in the NF were also migrated to this new DS subsection of the USP. However, many monographs for articles that continue to have excipient purposes remain as NF monographs, e.g., Peppermint, Peppermint Oil, and Peppermint Water; Licorice Root Fluidextract; and Cardamom, Cardamom Oil, and Cardamom Tincture. It should be noted, however, that other botanical articles in the USP–NF are not necessarily DSs. They may be classified as drugs (prescription or non-prescription), medical devices, or excipients. For example, Aloe, Belladonna Leaf, Digitalis, Elm, Ipecac, Opium, Podophyllum, Psyllium Husk, Rauwolfia Serpentina, Senna Leaf, and Senna Pod remain in the drug section of the USP [Note: Monograph titles are indicated in bold font]. There is a USP monograph for Gutta Percha, which is used as a medical device material for endodontic (root canal) treatment. Other articles for purposes such as flavors, fragrances, and other excipients, e.g., Rose Oil, are placed in the NF. The creation of monograph titles for vitamin and mineral articles is more straightforward than for botanical articles. Vitamin and mineral articles are mostly comprised of single ingredients with titles formulated in a manner similar to those for drugs. Guidance to develop botanical monograph titles was provided in the first USP in 1820, in which the guideline approach was to adopt a nomenclature to “…be conformable to the present language of science, divested of as much of its prolixity as can be done consistently with clearness and distinctness. It is conceded that the essential properties of names ought to be expressiveness, brevity and dissimilarity.” The intent was that the monograph title “…expresses the medicine, and nothing else; …needed to be short and explicit, and does not require to be mutilated in practical use, as long names will inevitably be” (2). Thus, a monograph title was to be brief and distinct; a single word sufficed if that word was expressive and unambiguous. DS Monograph Titles and DS Product Label Regulatory Requirements Paragraph 3(a) of DSHEA states that a DS shall be deemed to be a food (i.e., neither an over-the-counter nor prescription drug) within the meaning of this Act. The Act defines a DS as: “(1) a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the following dietary ingredients: (A) a vitamin; (B) G01.17-01 Page 3 of 44 EFFECTIVE DATE 03\17\ 2020 Guideline for Assigning Titles to USP Dietary Supplement Monographs a mineral; (C) a herb or other botanical; (D) an amino acid; (E) a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or (F) a concentrate, metabolite, constituent, extract, or combination of any ingredient described in clause (A), (B), (C), (D), or (E).”1 The Act also requires the label of a DS to identify the name of each ingredient. As set out in the Code of Federal Regulations Title 21 (21 CFR) section 101.4 (h)2, the “common or usual names of ingredients of dietary supplements that are botanicals (including fungi and algae) shall be consistent with the names standardized in Herbs of Commerce, 1992 edition” (HoC1) (3). Although DS monograph titles are not subject to DSHEA and federal product labeling requirements, to make the monographs as useful as possible to stakeholders, USP is assigning titles to DS monographs in a manner as consistent as possible with DSHEA and HoC. This includes the use of HoC Standardized Common Names (SCNs) of botanicals utilized in North American commerce and the use of common or usual names appearing in commerce when there is no SCN or HoC Other Common Name (OCN). It should be noted that USP’s DS monograph titles are required on labels of products purporting to be USP grade, but other titles may be used on labels of products not purporting to be USP grade as long as they are compliant with the federal regulations. Since the incorporation of HoC1 by reference into 21 CFR 101.4 (h), a second edition, HoC2, was published in 2000 (4). Some changes from HoC1 to HoC2, beyond the addition of more herbs of commerce, include revisions to common names and Latin binomials and the dropping of hyphens from Pinyin Names (Pinyin is the standard system of Romanized spelling for transliterating Chinese).
Recommended publications
  • Bifidobacterium Response to Lactulose Ingestion in the Gut Relies on A
    ARTICLE https://doi.org/10.1038/s42003-021-02072-7 OPEN Bifidobacterium response to lactulose ingestion in the gut relies on a solute-binding protein- dependent ABC transporter ✉ Keisuke Yoshida 1 , Rika Hirano2,3, Yohei Sakai4, Moonhak Choi5, Mikiyasu Sakanaka 5,6, Shin Kurihara3,6, Hisakazu Iino7, Jin-zhong Xiao 1, Takane Katayama5,6 & Toshitaka Odamaki1 This study aims to understand the mechanistic basis underlying the response of Bifido- bacterium to lactulose ingestion in guts of healthy Japanese subjects, with specific focus on a lactulose transporter. An in vitro assay using mutant strains of Bifidobacterium longum subsp. 1234567890():,; longum 105-A shows that a solute-binding protein with locus tag number BL105A_0502 (termed LT-SBP) is primarily involved in lactulose uptake. By quantifying faecal abundance of LT-SBP orthologues, which is defined by phylogenetic analysis, we find that subjects with 107 to 109 copies of the genes per gram of faeces before lactulose ingestion show a marked increase in Bifidobacterium after ingestion, suggesting the presence of thresholds between responders and non-responders to lactulose. These results help predict the prebiotics- responder and non-responder status and provide an insight into clinical interventions that test the efficacy of prebiotics. 1 Next Generation Science Institute, RD Division, Morinaga Milk Industry Co., Ltd., Zama, Japan. 2 Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Nonoichi, Japan. 3 Biology-Oriented Science and Technology, Kindai University, Kinokawa, Japan. 4 Food Ingredients and Technology Institute, RD Division, Morinaga Milk Industry Co., Ltd, Zama, Japan. 5 Graduate School of Biostudies, Kyoto University, Kyoto, Japan. 6 Faculty of Bioresources and Environmental Sciences, Ishikawa Prefectural University, Nonoichi, Japan.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski Et Al
    USOO9421 180B2 (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski et al. (45) Date of Patent: Aug. 23, 2016 (54) ANTIOXIDANT COMPOSITIONS FOR 6,203,817 B1 3/2001 Cormier et al. .............. 424/464 TREATMENT OF INFLAMMATION OR 6,323,232 B1 1 1/2001 Keet al. ............ ... 514,408 6,521,668 B2 2/2003 Anderson et al. ..... 514f679 OXIDATIVE DAMAGE 6,572,882 B1 6/2003 Vercauteren et al. ........ 424/451 6,805,873 B2 10/2004 Gaudout et al. ....... ... 424/401 (71) Applicant: Perio Sciences, LLC, Dallas, TX (US) 7,041,322 B2 5/2006 Gaudout et al. .............. 424/765 7,179,841 B2 2/2007 Zielinski et al. .. ... 514,474 (72) Inventors: Jan Zielinski, Vista, CA (US); Thomas 2003/0069302 A1 4/2003 Zielinski ........ ... 514,452 Russell Moon, Dallas, TX (US); 2004/0037860 A1 2/2004 Maillon ...... ... 424/401 Edward P. Allen, Dallas, TX (US) 2004/0091589 A1 5, 2004 Roy et al. ... 426,265 s s 2004/0224004 A1 1 1/2004 Zielinski ..... ... 424/442 2005/0032882 A1 2/2005 Chen ............................. 514,456 (73) Assignee: Perio Sciences, LLC, Dallas, TX (US) 2005, 0137205 A1 6, 2005 Van Breen ..... 514,252.12 2005. O154054 A1 7/2005 Zielinski et al. ............. 514,474 (*) Notice: Subject to any disclaimer, the term of this 2005/0271692 Al 12/2005 Gervasio-Nugent patent is extended or adjusted under 35 et al. ............................. 424/401 2006/0173065 A1 8/2006 BeZwada ...................... 514,419 U.S.C. 154(b) by 19 days. 2006/O193790 A1 8/2006 Doyle et al.
    [Show full text]
  • Recursos Naturales - Referencias Bibliográficas
    Recursos Naturales - Referencias Bibliográficas Nombre Nombre # Referencia Común Científico Afsar Shaik; Rupesh S Kanhere; Rajaram Cuddapah; Nelson Kumar S; Artemisa, Artemisia Prasanth Reddy Vara; Saisaran Sibyala. Antifertility activity of Artemisia 1 Mugwort vulgaris L. vulgaris leaves on female Wistar rats. Chinese Journal of Natural Medicines 2014, 12(3): 0180-0185 Diandra Araújo Luz, Alana Miranda Pinheiro; Mallone Lopes Silva; Marta Chagas Monteiro; Rui Daniel Prediger; Cristiane Socorro Ferraz Maia; Petiveria 2 Anamú Enéas Andrade Fontes-Júnior. Ethnobotany, phytochemistry and alliacea L. neuropharmacological effects of Petiveria alliacea L. (Phytolaccaceae): A review. Journal of Ethnopharmacology 185 (2016) 182–201 Plantago B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 4° 3 Llantén major L. Edición. p334-335 Turnera B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 3° 4 Damiana diffusa Wild. Edición. p178-179. var. Aesculus Castaño de B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 3° 5 hippocastanu Indias Edición. p172-175 m 1.- Chung-Hua Hsu & Col. The Mushroom Agaricus blazei Murill Extract Normalizes Liver Function in Patients with Chronic Hepatitis B. The Journal of Alternative and Complementary Medicine. Volume 14, Number 3, 2008, pp. 299–301 2.- Diogo G. Valadares, Mariana C. Duarte, Laura Ramírez, Miguel A. Chávez-Fumagalli, Eduardo A.F. Coelho. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis. Experimental Parasitology, Volume 132, Issue 2, October 2012, Pages 228-236 6 Setas Agaricus blazei 3.- Chung-Hua Hsu & Col. The Mushroom Agaricus blazei Murill in Combination with Metformin and Gliclazide Improves Insulin Resistance in Type 2 Diabetes: A Randomized, Double-Blinded, and Placebo- Controlled Clinical Trial.
    [Show full text]
  • Delivery of Metabolically Neuroactive Probiotics to the Human Gut
    International Journal of Molecular Sciences Article Delivery of Metabolically Neuroactive Probiotics to the Human Gut Peter A. Bron 1, Marta Catalayud 2 , Massimo Marzorati 2,3, Marco Pane 3, Ece Kartal 4 , Raja Dhir 1 and Gregor Reid 5,6,* 1 Seed Health, 2100 Abbot Kinney Blvd Suite G Venice, Los Angeles, CA 90291, USA; [email protected] (P.A.B.); [email protected] (R.D.) 2 ProDigest BV, Technologiepark-Zwijnaarde 94, 9052 Gent, Belgium; [email protected] (M.C.); [email protected] (M.M.) 3 Probioticial, Via Enrico Mattei 3, 28100 Novara, Italy; [email protected] 4 Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Heidelberg University, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany; [email protected] 5 Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, 268 Grosvenor Street, London, ON N6A 4V2, Canada 6 Departments of Microbiology and Immunology, and Surgery, Western University, London, ON N6A 3K7, Canada * Correspondence: [email protected] Abstract: The human microbiome is a rich factory for metabolite production and emerging data has led to the concept that orally administered microbial strains can synthesize metabolites with neuroactive potential. Recent research from ex vivo and murine models suggests translational potential for microbes to regulate anxiety and depression through the gut-brain axis. However, so far, less emphasis has been placed on the selection of specific microbial strains known to produce the required key metabolites and the formulation in which microbial compositions are delivered to the Citation: Bron, P.A.; Catalayud, M.; gut. Here, we describe a double-capsule technology to deliver high numbers of metabolically active Marzorati, M.; Pane, M.; Kartal, E.; Dhir, R.; Reid, G.
    [Show full text]
  • Our Probiotic Strains Str Ou Ainsr Or Pr S Tobioic
    THERAPEUTIC IndEx GAStroenteroloGy pag. 5 OUROUR PROBIOTICPROOBIOTTIC ImmunoloGy pag. 17 DermAtoloGy pag. 21 STRAINSSTRRAINSS AntI-AGInG pag. 23 CArDIoloGy/ metAbolISm pag. 27 DIetetICS pag. 29 GIneColoGy pag. 31 uroloGy pag. 39 Gut-brAIn pag. 43 Probiotics like nobody else OurOur InnovativeInnovative orAl CAre pag. 47 Probiotical S.p.A. Via E. Mattei, 3, 28100 Novara (NO), Italy - T: +39 0321 46 59 33 61 Strains:Sttrains:i F: +39 0321 49 26 93 - email: [email protected] - www.probiotical.com teChnoloGIeS pag. 49 ReadyReaddy forfor YourYour HealthHeallth tHeraPeUtiC index GastroenteroloGy pag. 5 ImmunoloGy pag. 17 DermatoloGy pag. 20 antI-aGInG pag. 22 CarDIoloGy/metabolIsm pag. 25 DIetetICs pag. 27 GIneColoGy pag. 29 uroloGy pag. 37 Gut-braIn pag. 41 oral Care pag. 44 teChnoloGIes pag. 45 Romane Catalogo Indice 13-5-20:Layout 1 26/05/20 17:44 Pagina 1 Probiotical is driving probiotics innovation since 1985. Our expertise comprises strain selection, advanced R&D, production of strains to finished products with all guarantees of stability and demonstrated efficacy in many functionalities. Our strains can be proposed in allergen-free quality, microencapsulated, and standardized in different concentrations. Strains available as raw material can be provided in bulk or as customized finished products. Strains available as finished dosage form can be provided only as Probiotical finished products. Romane Catalogo Indice 13-5-20:Layout 1 26/05/20 17:44 Pagina 3 StrainS & blendS index Bifidobacterium • Bifidobacterium breve - BR03™ (DSM 16604) Gastroenterology: Strain: pag. 8, 15 - Blend: pag. 5, 6, 8, 10, 14 ; Dermatology: Blend: pag. 21 ; Dietetics: Strain: pag.
    [Show full text]
  • PROBIOTICS, PREBIOTICS NEW FOODS, NUTRACEUTICALS and BOTANICALS for NUTRITION & HUMAN and MICROBIOTA HEALTH SCIENTIFIC ORGANISERS L
    rome - september 10/12, 2017 università urbaniana PROBIOTICS, PREBIOTICS NEW FOODS, NUTRACEUTICALS AND BOTANICALS for NUTRITION & HUMAN and MICROBIOTA HEALTH SCIENTIFIC ORGANISERS L. Capurso (Italy) A. Gasbarrini (Italy) A. Guarino (Italy) L. Morelli (Italy) INTERNATIONAL SCIENTIFIC COMMITTEE G. Barbara (Italy) R. Berni CananiPROBIOTICS, (Italy) PREBIOTICS P. Brigidi (Italy) M. L. Colombo NEW (Italy) FOODS, NUTRACEUTICALS AND BOTANICALS G. Delle Favefor NUTRITION(Italy) & HUMAN and MICROBIOTA HEALTH J. Dorè (France) V. Fogliano (The Netherlands) F. Guarner (Spain) M. Rescigno (Italy) H. Tilg (Austria) K. M. Tuohy (Italy) PEDIATRIC DAY A. Guarino (Italy) SCIENTIFIC REFEREES M. Anti (Italy) G. Capurso (Italy) M. Koch (Italy) UNDER THE PATRONAGE OF UNDER THE PATRONAGE OF Associazione Giovani Gastroenterologi ed Endoscopisti Italiani SIGE, Società Italiana di Gastroenterologia European Association for Gastroenterology, Endoscopy & Nutrition 5/7/2017 logo.JPG MTCC, Mediterranean Task Force for Cancer Control https://mail.google.com/mail/u/0/#inbox?projector=1 1/1 index Sunday, September 10 Aula Magna p. 8 Aula Élie Metchnikoff p. 11 Monday, September 11 Aula Magna p. 15 Aula Élie Metchnikoff p. 18 Tuesday, September 12 Aula Magna p. 20 Aula Élie Metchnikoff p. 22 Proceedings p. 27 Oral Communications p. 75 Posters p. 89 Faculty p. 126 Index of Authors p. 130 SCIENTIFIC PROGRAMME Abstract Authors Countries p. 133 General Information p. 134 Scientific Information p. 139 Exhibition Area p. 142 aula magna sunday, SEPTEMBER 10 sunday, SEPTEMBER 10 AULA magna 08.30-10.00 a.m. YOUNG ITALIAN GASTROENTEROLOGISTS (AGGEI) 02.00-03.00 p.m. OPENING CEREMONY MEET THE EXPERT: QUESTIONS AND ANSWERS Chairs: L.
    [Show full text]
  • Cosmeceutical Importance of Fermented Plant Extracts: a Short Review
    International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 10, Issue 4, 2018 Review Article COSMECEUTICAL IMPORTANCE OF FERMENTED PLANT EXTRACTS: A SHORT REVIEW BHAGAVATHI SUNDARAM SIVAMARUTHI, CHAIYAVAT CHAIYASUT, PERIYANAINA KESIKA * Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand Email: [email protected] Received: 30 Mar 2018, Revised and Accepted: 24 May 2018 ABSTRACT Personal care products, especially cosmetics, are regularly used all over the world. The used cosmetics are discharged continuously into the environment that affects the ecosystem and human well-being. The chemical and synthetic active compounds in the cosmetics cause some severe allergies and unwanted side effects to the customers. Currently, many customers are aware of the product composition, and they are stringent in product selection. So, cosmetic producers are keen to search for an alternative, and natural active principles for the development and improvisation of the cosmetic products to attain many customers. Phytochemicals are known for several pharmacological and cosmeceutical applications. Fermentation process improved the quality of the active phytochemicals and also facilitates the easy absorption of them by human system. Recently, several research groups are working on the cosmeceutical importance of fermented plant extracts (FPE), particularly on anti-ageing, anti-wrinkle, and whitening property of FPE. The current manuscript is presenting a brief
    [Show full text]
  • GRAS Notice 855, Bifidobacterium Animalis Subsp. Lactis Strain R0421
    GRAS Notice (GRN) No. 855 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory JHeimbach LLC April 3, 2019 Paulette Gaynor, Ph.D. Senior Regulatory Project Manager Division of Biotechnology and GRAS Notice Review (HFS-255) Office of Food Additive Safety Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740 Dear Dr. Gaynor: Pursuant to 21 CFR Part 170, Subpart E, Lallemand Health Solutions (Lallemand), through me as its agent, hereby provides notice of a claim that the addition to non-exempt milk-based term infant formula of Bifidobacteriurn anirnalis ssp. lactis strain R0421 is exempt from the premarket approval requirement of the Federal Food, Drug, and Cosmetic Act because Lallemand has determined that the intended use is generally recognized as safe (GRAS) based on scientific procedures. As required, one copy of the GRAS monograph and one signed copy of the statement of the Expert Panel are provided. Additionally, I have enclosed a virus-free CD-ROM with the GRAS monograph and the signed statement of the Expert Panel. If you have any questions regarding this notification, please feel free to contact me at 804-742-5543 o~ jheimbach.com. Si11~1/ ""James t. Heimbach, Ph.D., F.A.C.N. President Encl. ~~~~u~~lg) APR 8 2019 OFFICE OF 923 Water Street, P.O. Box 66, Port Royal Virginia 22535, USA FOOD ADDITl\/1: SAFETY tel. (+1) 804-742-5543 fax (+1) 202-478-0986 [email protected] LALLEMAND HEALTH SOLUTIONS Generally Recognized as Safe (GRAS) Determination for the Use of Bifidobacterium animalis subsp.
    [Show full text]
  • USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements
    USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements U.S. PHARMACOPEIAL CONVENTION The United States Pharmacopeial Convention Urges Scientific Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements (Rockville, MD – April 16, 2015) – In response to an agreement announced between the New York State Attorney General (NYAG) and GNC Holdings, Inc. (GNC) the United States Pharmacopeial Convention (USP), an independent, science based, standards setting organization and publishers of the United States Pharmacopeia-National Formulary (USP-NF), an official compendia of quality standards for dietary supplements sold in the U.S., issued the following statement: Statement by Gabriel Giancaspro, PhD – Vice President –Foods, Dietary Supplement and Herbal Medicines United States Pharmacopeial Convention (USP) “As a science-based standards-setting organization, the United States Pharmacopeial Convention (USP) has a keen interest in adopting emerging technologies to ensure the test methods and quality standards included in the United States Pharmacopeia-National Formulary (USP-NF) are current and reflect the state of the industry. DNA testing including DNA Barcoding, is just one example of a technology that has been recently added to the USP-NF. As of December 2014, DNA-based identification methods are included in the official USP chapter <563> Identification of Articles of Botanical Origin. However, this method is not yet referenced in a USP-NF monograph (quality standard) for a specific ingredient or product. That is because USP quality standards are specific for each ingredient, product and dosage form and the standards we develop include only those test methods that have been scientifically validated and shown to be fit for purpose.
    [Show full text]
  • Tolerance and Safety of Lactobacillus Paracasei Ssp. Paracasei in Combination with Bifidobacterium Animalis Ssp
    Downloaded from British Journal of Nutrition (2009), 102, 869–875 doi:10.1017/S0007114509289069 q The Authors 2009 https://www.cambridge.org/core Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial . IP address: Arine M. Vlieger1*, Afke Robroch1, Stef van Buuren2,3, Jeroen Kiers4,5, Ger Rijkers6, 7 4 Marc A. Benninga and Rob te Biesebeke 170.106.202.8 1Department of Paediatrics, St Antonius Hospital, Nieuwegein, The Netherlands 2Department of Statistics, TNO Quality of Life, Leiden, The Netherlands 3 Department of Methodology and Statistics, FSS, University of Utrecht, The Netherlands , on 4 Global Development Centre, Friesland Foods, Leeuwarden, The Netherlands 26 Sep 2021 at 01:49:26 5NIZO, Ede, The Netherlands 6Department of Microbiology and Immunology, St Antonius Hospital, Nieuwegein, The Netherlands 7Department of Paediatric Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands (Received 11 September 2008 – Revised 29 January 2009 – Accepted 3 February 2009 – First published online 31 March 2009) , subject to the Cambridge Core terms of use, available at The addition of probiotics to infant formula has been shown to be an efficient way to increase the number of beneficial bacteria in the intestine in order to promote a gut flora resembling that of breast-fed infants. The objective of the present study was to evaluate the safety and tolerance of a combination of two probiotic strains in early infancy. A group of 126 newborns were randomised to receive a prebiotic-containing starter formula supplemented with Lactobacillus paracasei ssp. paracasei and Bifidobacterium animalis ssp.
    [Show full text]
  • The Pennsylvania State University the Graduate School Department
    The Pennsylvania State University The Graduate School Department of Food Science EFFECT OF STARCH SPHERULITES ON SURVIVAL OF BIFIDOBACTERIA IN THE PRESENCE OF ACID OR BILE A Thesis in Food Science by Srilatha Chittiprolu 2009 Srilatha Chittiprolu Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science May 2009 ii The thesis of Srilatha Chittiprolu was reviewed and approved* by the following: Robert F. Roberts Associate Professor of Food Science Thesis Advisor Stephen J. Knabel Professor of Food Science Gregory R. Ziegler Professor of Food Science John D. Floros Professor of Food Science Head of the Department of Food Science *Signatures are on file in the Graduate School iii ABSTRACT Probiotics are live microorganisms which have been shown to confer a health benefit on the host, when administered in sufficient amounts (FAO/WHO, 2001). Many of the probiotic bacteria currently used in foods and dietary supplements are members of Lactic Acid Bacteria. Strains of the genus Bifidobacterium are widely used as probiotics for human consumption. Bifidobacteria are often sensitive to stresses encountered during production and storage of food and during passage through the gastrointestinal tract. Thus, the overall purpose of this research was to determine if adhesion of bifidobacteria to starch-based spherulites can improve their survival when exposed to acid or bile. The first objective of this work was to develop a procedure to prepare spherulites in adequate quantities for use in adhesion and survival studies. Spherulites were prepared successfully in a Parr reactor (pressure vessel) using potato starch, high amylose maize starch (Hylon VII) and purified potato amylose.
    [Show full text]
  • Insight Into Alternative Approaches for Control of Avian Influenza in Poultry, with Emphasis on Highly Pathogenic H5N1
    Viruses 2012, 4, 3179-3208; doi:10.3390/v4113179 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Insight into Alternative Approaches for Control of Avian Influenza in Poultry, with Emphasis on Highly Pathogenic H5N1 E. M. Abdelwhab †,* and Hafez M. Hafez Institute of Poultry Diseases, Free Berlin University, Königsweg 63, 14163 Berlin, Germany; E-Mail: [email protected] † Present address: Molecular Pathogenesis and Ecology of Influenza Viruses Laboratory, Institute of Molecular Biology, Federal Research Institute for Animal Health, Friedrich Loeffler Institute, Isles of Riems, Suedufer 10, 17493 Greifswald, Germany * Author to whom correspondence should be addressed; E-Mails: [email protected]; [email protected]; Tel.: +49-30-8386-2679; +49-38-3517-1263; +49-38-3517-1237; Fax: +49-30-838-6267; +49-38-3517-1275. Received: 23 September 2012; in revised form: 4 November 2012 / Accepted: 8 November 2012 / Published: 19 November 2012 Abstract: Highly pathogenic avian influenza virus (HPAIV) of subtype H5N1 causes a devastating disease in poultry but when it accidentally infects humans it can cause death. Therefore, decrease the incidence of H5N1 in humans needs to focus on prevention and control of poultry infections. Conventional control strategies in poultry based on surveillance, stamping out, movement restriction and enforcement of biosecurity measures did not prevent the virus spreading, particularly in developing countries. Several challenges limit efficiency of the vaccines to prevent outbreaks of HPAIV H5N1 in endemic countries. Alternative and complementary approaches to reduce the current burden of H5N1 epidemics in poultry should be encouraged. The use of antiviral chemotherapy and natural compounds, avian-cytokines, RNA interference, genetic breeding and/or development of transgenic poultry warrant further evaluation as integrated intervention strategies for control of HPAIV H5N1 in poultry.
    [Show full text]